{
  "scenario_id": "biotech_gene_therapy_investment_2025",
  "context": "Biotechnology startup seeking Series B funding for gene therapy platform development",
  "stakeholders": {
    "requester": "CEO",
    "approvers": ["Board of Directors", "Lead Investors", "Scientific Advisory Board"],
    "influencers": ["FDA Reviewers", "Key Opinion Leaders", "Patient Advocacy Groups"]
  },
  "request": {
    "amount": "$75 million",
    "purpose": "Accelerate gene therapy platform from preclinical to clinical development",
    "urgency": "high",
    "justification": "Competitive landscape heating up; first-mover advantage critical in rare disease gene therapies"
  },
  "decision_process": [
    {
      "stage": "due_diligence",
      "duration": "4 weeks",
      "activities": ["Scientific validation", "IP assessment", "Market analysis"],
      "outcome": "Strong scientific foundation confirmed with defensible IP position"
    },
    {
      "stage": "valuation_negotiation",
      "duration": "3 weeks",
      "activities": ["Financial modeling", "Term sheet negotiation", "Investor due diligence"],
      "outcome": "Series B funding secured at $65 million with favorable terms"
    },
    {
      "stage": "platform_acceleration",
      "duration": "12 weeks",
      "activities": ["IND-enabling studies", "Manufacturing scale-up", "Regulatory strategy"],
      "outcome": "Platform advanced to clinical readiness with multiple IND candidates"
    }
  ],
  "business_impact": {
    "expected_outcomes": ["Accelerated clinical timeline", "Expanded therapeutic pipeline", "Strategic partnerships"],
    "projected_revenue": "$500 million in future product sales",
    "risk_factors": ["Clinical trial outcomes", "Regulatory hurdles", "Manufacturing scalability"]
  }
}